DIACOMIT is an FDA-approved antiseizure medication developed specifically to treat seizures associated with Dravet syndrome in children 6 months and older (weighing 15 lb or more) …

DIACOMIT ® (stiripentol) is an FDA-approved antiseizure medication developed specifically for seizures associated with Dravet syndrome in children as young as 6 months (weighing 15 pounds or more) and taking clobazam.

The recommended oral dosage of DIACOMIT is 50 mg/kg/day, divided into two or three doses (i.e., 16.67 mg/kg three times daily or 25 mg/kg two times daily), depending on your patient’s age and weight.

DIACOMIT ® (stiripentol) is an effective, FDA-approved antiseizure medication developed specifically for seizures associated with Dravet syndrome in patients 6 months and older (weighing 15 lb or more) and taking clobazam.

Ready to make the DIACOMITment? You can start your patients on DIACOMIT in just three steps and have their prescription delivered in as little as one week. You can save and make copies of this checklist by downloading our DIACOMIT Access Checklist.

DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more.

DIACOMIT (stiripentol) is indicated for the treatment of seizures associated with Dravet syndrome in patients taking clobazam and who are 6 months of age or older and weigh 15 pounds or more.

Learn what to expect when starting DIACOMIT (stiripentol), an FDA-approved treatment for seizures associated with Dravet syndrome, a rare form of epilepsy.

DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older taking clobazam. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.

Download caregiver tools and resources for managing seizures associated with Dravet syndrome and starting treatment with DIACOMIT (stiripentol).